MENU
+Compare
DYN
Stock ticker: NASDAQ
AS OF
Dec 1 closing price
Price
$20.61
Change
-$1.29 (-5.89%)
Capitalization
2.94B

DYN Dyne Therapeutics Forecast, Technical & Fundamental Analysis

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases... Show more

DYN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for DYN with price predictions
Dec 01, 2025

DYN in +5.29% Uptrend, growing for three consecutive days on November 28, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where DYN advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 20, 2025. You may want to consider a long position or call options on DYN as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 243 cases where DYN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for DYN moved out of overbought territory on November 04, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Moving Average Convergence Divergence Histogram (MACD) for DYN turned negative on November 06, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DYN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DYN broke above its upper Bollinger Band on October 27, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.254) is normal, around the industry mean (27.247). P/E Ratio (0.000) is within average values for comparable stocks, (52.214). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.890). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (320.114).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DYN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DYN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
DYN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

DYN is expected to report earnings to rise 3.42% to -78 cents per share on February 26

Dyne Therapeutics DYN Stock Earnings Reports
Q4'25
Est.
$-0.79
Q3'25
Beat
by $0.08
Q2'25
Missed
by $0.03
Q1'25
Missed
by $0.20
Q4'24
Beat
by $0.06
The last earnings report on November 05 showed earnings per share of -75 cents, beating the estimate of -83 cents. With 1.61M shares outstanding, the current market capitalization sits at 2.94B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Electric Utilities
Address
1560 Trapelo Road
Phone
+1 781 786-8230
Employees
141
Web
https://www.dyne-tx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FIREX10.61N/A
N/A
Fidelity Intl Real Estate
APGAX109.75N/A
N/A
AB Large Cap Growth A
VMGRX28.87N/A
N/A
Vanguard Mid Cap Growth Inv
SIBLX30.88N/A
N/A
Touchstone Balanced Y
GGFSX20.31N/A
N/A
Gabelli Global Financial Services A

DYN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYN
1D Price
Change %
DYN100%
-5.94%
RNA - DYN
62%
Loosely correlated
-0.49%
IDYA - DYN
56%
Loosely correlated
-3.71%
SYRE - DYN
54%
Loosely correlated
-4.53%
XNCR - DYN
54%
Loosely correlated
-4.56%
CRNX - DYN
52%
Loosely correlated
-0.59%
More